ES8706114A1 - Procedimiento para preparar (r)-alfa-etil-2-oxo-1-pirrolidinacetamida (comodivisional de la solicitud de patente de invencion num. 543.125, presentada el 14.5.1985) - Google Patents
Procedimiento para preparar (r)-alfa-etil-2-oxo-1-pirrolidinacetamida (comodivisional de la solicitud de patente de invencion num. 543.125, presentada el 14.5.1985)Info
- Publication number
- ES8706114A1 ES8706114A1 ES551366A ES551366A ES8706114A1 ES 8706114 A1 ES8706114 A1 ES 8706114A1 ES 551366 A ES551366 A ES 551366A ES 551366 A ES551366 A ES 551366A ES 8706114 A1 ES8706114 A1 ES 8706114A1
- Authority
- ES
- Spain
- Prior art keywords
- radical
- oxo
- alpha
- ethyl
- pyrrolidinacetamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 title abstract 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 abstract 2
- IODGAONBTQRGGG-ZCFIWIBFSA-N (2r)-2-(2-oxopyrrolidin-1-yl)butanoic acid Chemical compound CC[C@H](C(O)=O)N1CCCC1=O IODGAONBTQRGGG-ZCFIWIBFSA-N 0.000 abstract 1
- HNNJFUDLLWOVKZ-GSVOUGTGSA-N (2r)-2-aminobutanamide Chemical compound CC[C@@H](N)C(N)=O HNNJFUDLLWOVKZ-GSVOUGTGSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 229910021529 ammonia Inorganic materials 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Detergent Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cephalosporin Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
METODO DE PREPARAR (R)-ALFA-ETIL-2-OXO-1-PIRROLIDIN-ACETAMIDA.CONSISTE EN CICLIZAR, EN UN DISOLVENTE INERTE TAL COMO TOLUENO, EN PRESENCIA DE UNA SUSTANCIA BASICA Y A TEMPERATURA ENTRE 0JC Y LA TEMPERATURA DE EBULLICION DEL DISOLVENTE EMPLEADO, UNA (R)-2-AMINO-BUTANAMIDA DE FORMULA X-CH2CH2-Y-NHCH(C2H5)CONH2 EN LA QUE X REPRESENTA UN RADICAL ZOOC O HALCH2, SIENDO Z UN RADICAL ALQUILO DE C 1 A 4 Y HAL UN ATOMO DE HALOGENO, E Y REPRESENTA UN RADICAL CH2 O CO, CON LA RESTRICCION DE QUE CUANDO X REPRESENTA UN RADICAL ZOOC, Y ES UN RADICAL CH2 Y CUANDO X REPRESENTA UN RADICAL HALCH2, Y ES UN RADICAL CO. TIENEN APLICACIONES FARMACEUTICAS PARA EL TRATAMIENTO DE HIPERQUINESIAS, HIPERTONIAS Y EPILEPSIA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB848412358A GB8412358D0 (en) | 1984-05-15 | 1984-05-15 | Pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES8706114A1 true ES8706114A1 (es) | 1987-06-01 |
| ES551366A0 ES551366A0 (es) | 1987-06-01 |
Family
ID=10560975
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES543125A Expired ES8703419A1 (es) | 1984-05-15 | 1985-05-14 | Procedimiento para preparar (r)-alfa-etil-2-oxo-1-pirrolidi-nacetamida |
| ES551366A Expired ES8706114A1 (es) | 1984-05-15 | 1986-01-29 | Procedimiento para preparar (r)-alfa-etil-2-oxo-1-pirrolidinacetamida (comodivisional de la solicitud de patente de invencion num. 543.125, presentada el 14.5.1985) |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES543125A Expired ES8703419A1 (es) | 1984-05-15 | 1985-05-14 | Procedimiento para preparar (r)-alfa-etil-2-oxo-1-pirrolidi-nacetamida |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US4696942A (es) |
| EP (1) | EP0165919B1 (es) |
| JP (1) | JPS60255764A (es) |
| AT (1) | ATE45348T1 (es) |
| AU (1) | AU574175B2 (es) |
| BG (2) | BG60030B2 (es) |
| CA (1) | CA1237138A (es) |
| CY (1) | CY1568A (es) |
| DE (1) | DE3572168D1 (es) |
| DK (1) | DK163500C (es) |
| ES (2) | ES8703419A1 (es) |
| FI (1) | FI80674C (es) |
| GB (1) | GB8412358D0 (es) |
| GR (1) | GR851156B (es) |
| HK (1) | HK62692A (es) |
| IE (1) | IE58393B1 (es) |
| IL (1) | IL75180A (es) |
| NO (1) | NO164535C (es) |
| PL (2) | PL144345B1 (es) |
| PT (1) | PT80461B (es) |
| SG (1) | SG80190G (es) |
| SU (3) | SU1417799A3 (es) |
| ZA (1) | ZA853636B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8412357D0 (en) * | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
| DE3420193A1 (de) * | 1984-05-30 | 1985-12-05 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue substituierte pyrrolidinone, verfahren zu ihrer herstellung und arzneimittel |
| GB8827389D0 (en) * | 1988-11-23 | 1988-12-29 | Ucb Sa | Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide |
| US6124473A (en) * | 1998-05-08 | 2000-09-26 | Ucb, S.A. | Process for preparing (s)- and (R)-α-ethyl-2-oxo-1-pyrrolidineacetamide |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| WO2002042256A2 (en) * | 2000-11-21 | 2002-05-30 | Ucb, S.A. | N-alkylated gaba compounds, processes for their preparation and their use as medicaments |
| EP1392290B1 (en) * | 2001-03-22 | 2005-05-18 | Ucb, S.A. | Use of certain substituted pyrrolidones such as piracetam in the treatment of viral and other diseases |
| IL160045A0 (en) * | 2001-08-10 | 2004-06-20 | Ucb Sa | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues |
| ES2323313T3 (es) | 2003-12-02 | 2009-07-13 | Ucb Pharma, S.A. | Derivados de imidazol, procedimientos para prepararlos y sus usos. |
| CA2488325C (en) * | 2004-11-22 | 2010-08-24 | Apotex Pharmachem Inc. | Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide |
| EP2308870A3 (en) | 2005-06-01 | 2011-10-19 | UCB Pharma S.A. | 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses |
| CN102227217A (zh) * | 2008-10-16 | 2011-10-26 | 约翰斯.霍普金斯大学 | 改善认知功能的方法和组合物 |
| CN102574869A (zh) | 2009-10-23 | 2012-07-11 | Ucb医药有限公司 | 2-氧代-1-吡咯烷基咪唑并噻二唑衍生物 |
| EA037187B1 (ru) | 2010-02-09 | 2021-02-17 | Дзе Джонс Хопкинс Юниверсити | Способ и композиция для лечения когнитивного расстройства |
| DK2699581T3 (en) | 2011-04-18 | 2016-01-11 | Ucb Biopharma Sprl | 2-oxo-1-IMIDAZOLIDINYLIMIDAZOTHIADIAZOLDERIVATIVER |
| CN102633675A (zh) * | 2012-04-10 | 2012-08-15 | 南京大学 | 一种dl-2-氨基丁酰胺制备方法 |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| WO2014144801A1 (en) | 2013-03-15 | 2014-09-18 | Agenebio Inc. | Methods and compositions for improving cognitive function |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| LT3096790T (lt) | 2014-01-21 | 2019-10-10 | Janssen Pharmaceutica, N.V. | Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas |
| WO2015110435A1 (en) | 2014-01-21 | 2015-07-30 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| US10925834B2 (en) | 2015-05-22 | 2021-02-23 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| JOP20210082A1 (ar) | 2018-12-04 | 2023-01-30 | Metys Pharmaceuticals AG | تركيبات تآزرية تشتمل على (r)-2-(2-أوكسو بيروليدين-1-يل)بيوتان أميد و(s)-2-(2-أوكسو بيروليدين-1-يل)بيوتان أميد بنسبة غير راسيمية |
| US11384050B1 (en) | 2021-02-03 | 2022-07-12 | Vitaworks Ip, Llc | Method for preparing levetiracetam and intermediates thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1309692A (en) * | 1970-02-13 | 1973-03-14 | Ucb Sa | N-substituted lactams |
| GB1583871A (en) * | 1976-10-19 | 1981-02-04 | Ucb Sa | Anti-aggregants |
| FR2418790A1 (fr) * | 1978-03-02 | 1979-09-28 | Philagro Sa | Nouveaux derives de pyrrolidinone-2 et compositions herbicides les contenant |
| AU579863B2 (en) * | 1984-05-16 | 1988-12-15 | Williams, David Andrew | A parking control apparatus |
-
1984
- 1984-05-15 GB GB848412358A patent/GB8412358D0/en active Pending
-
1985
- 1985-05-13 GR GR851156A patent/GR851156B/el unknown
- 1985-05-13 IL IL75180A patent/IL75180A/xx unknown
- 1985-05-13 FI FI851876A patent/FI80674C/fi not_active IP Right Cessation
- 1985-05-14 JP JP60102530A patent/JPS60255764A/ja active Pending
- 1985-05-14 DE DE8585870068T patent/DE3572168D1/de not_active Expired
- 1985-05-14 DK DK212885A patent/DK163500C/da not_active IP Right Cessation
- 1985-05-14 ZA ZA853636A patent/ZA853636B/xx unknown
- 1985-05-14 PL PL1985253373A patent/PL144345B1/pl unknown
- 1985-05-14 BG BG94053A patent/BG60030B2/bg unknown
- 1985-05-14 PT PT80461A patent/PT80461B/pt not_active IP Right Cessation
- 1985-05-14 EP EP85870068A patent/EP0165919B1/fr not_active Expired
- 1985-05-14 NO NO851934A patent/NO164535C/no not_active IP Right Cessation
- 1985-05-14 PL PL1985257386A patent/PL147387B1/pl unknown
- 1985-05-14 BG BG70237A patent/BG50272A3/xx unknown
- 1985-05-14 AT AT85870068T patent/ATE45348T1/de not_active IP Right Cessation
- 1985-05-14 CA CA000481511A patent/CA1237138A/en not_active Expired
- 1985-05-14 ES ES543125A patent/ES8703419A1/es not_active Expired
- 1985-05-14 SU SU3892951A patent/SU1417799A3/ru active
- 1985-05-14 US US06/733,791 patent/US4696942A/en not_active Expired - Lifetime
- 1985-05-14 IE IE119285A patent/IE58393B1/en not_active IP Right Cessation
- 1985-05-14 AU AU42529/85A patent/AU574175B2/en not_active Ceased
- 1985-10-25 SU SU853968801A patent/SU1320207A1/ru active
-
1986
- 1986-01-29 ES ES551366A patent/ES8706114A1/es not_active Expired
- 1986-08-13 SU SU4027936A patent/SU1428194A3/ru active
-
1987
- 1987-03-12 US US07/025,278 patent/US4837224A/en not_active Expired - Lifetime
-
1990
- 1990-10-02 SG SG801/90A patent/SG80190G/en unknown
-
1991
- 1991-12-20 CY CY1568A patent/CY1568A/xx unknown
-
1992
- 1992-08-20 HK HK626/92A patent/HK62692A/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY101725A (en) | (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide. | |
| ES8706114A1 (es) | Procedimiento para preparar (r)-alfa-etil-2-oxo-1-pirrolidinacetamida (comodivisional de la solicitud de patente de invencion num. 543.125, presentada el 14.5.1985) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD1A | Patent lapsed |
Effective date: 20041102 |